Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics...
Stay updated with breaking news from Cameron Turtle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics...
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc....
AUSTIN, Texas and WALTHAM, Mass., June 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (
Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD)...
SAN FRANCISCO, Dec. 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on ...